KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 3,125 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $30,687.50. Following the sale, the insider now owns 100,334 shares of the company’s stock, valued at $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Up 9.5 %

KalVista Pharmaceuticals stock traded up $0.93 during mid-day trading on Wednesday, hitting $10.71. 515,932 shares of the stock were exchanged, compared to its average volume of 304,464. The stock has a market capitalization of $529.29 million, a price-to-earnings ratio of -2.94 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The firm’s fifty day simple moving average is $8.80 and its two-hundred day simple moving average is $10.43.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of KALV. Aquatic Capital Management LLC bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth about $44,000. Tower Research Capital LLC TRC grew its holdings in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc increased its position in shares of KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 1,494 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after acquiring an additional 3,328 shares in the last quarter. Finally, Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter worth about $86,000.

Analyst Ratings Changes

KALV has been the topic of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Thursday, December 5th. Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They issued an “outperform” rating and a $19.00 target price for the company. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).